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ABSTRACT
Gonadotropin-releasing hormone (GnRH) receptor agonists
have wide clinical applications including the treatment of pros-
tate cancer and endocrine disorders. However, such agonists
are characterized by poor pharmacokinetic properties, often
requiring repeated administration or special formulations.
Therefore, the development of novel peptide analogs with en-
hanced in vivo stability could potentially provide therapeutic
alternatives. The pharmacological evaluation of a bioactive
peptide [Des-Gly10,Tyr5(OMe),D-Leu6,Aze-NHEt9]GnRH, ana-
log 1, is presented herein and compared with leuprolide. Pep-
tide stability was evaluated using mouse kidney membrane
preparations, followed by a liquid chromatography-tandem
mass spectrometry-based approach that afforded identifica-
tion and quantification of its major metabolites. The analog was
significantly more stable in vitro in comparison with leuprolide.
In vitro and in vivo stability results correlated well, encouraging
us to develop a clinically relevant pharmacokinetic mouse
model, which facilitated efficacy measurements using testos-
terone as a biomarker. Analog 1, an agonist of the GnRH
receptor with a binding affinity in the nanomolar range, caused
testosterone release in mice that was acutely dose-dependent,
an effect blocked by the GnRH receptor antagonist cetrorelix.
Repeated dosing studies in mice demonstrated that analog 1
was well tolerated and had potency similar to that of leuprolide,
based on plasma and testis testosterone reduction and histo-
pathological findings. Analog 1 also shared with leuprolide
similar significant antiproliferative activity on androgen-depen-
dent prostate cancer (LNCaP) cells. On the basis of pharma-
cokinetic advantages, we expect that analog 1 or analogs
based on this new design will be therapeutically advantageous
for the treatment of cancer and endocrine disorders.
Introduction
Androgen deprivation therapy with gonadotropin-releas-
ing hormone (GnRH) analogs is considered to be the first-line
treatment for patients with prostate cancer. In early-stage
prostate cancer, disease development and progression are
mediated by androgens and growth and survival factors that
promote cell proliferation and inhibit apoptosis. A significant
proportion of patients develop locally advanced or metastatic
disease not amenable to surgery or radiotherapy (Labrie et
al., 2005). Recent advances suggest that GnRH analogs not
only inhibit testicular androgen secretion via the pituitary-
gonadal axis but are also capable of direct inhibition of tumor
growth, exerting specific (receptor-mediated) antiprolifera-
tive, antimitogenic, and antimetastatic activities on cancer
cells (Montagnani Marelli et al., 2006, 2007). Because several
types of cancer cells overexpress the GnRH receptor, novel
structures based on GnRH analogs that act as carriers to
cancer cells, coupled with cytotoxic molecules (e.g., doxorubi-
cin), have been prepared and evaluated in preclinical cancer
models with promising results (Mezo and Manea, 2010).
Chronic administration of GnRH analogs results in the
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desensitization of the GnRH receptor and, hence, medical
castration (Maudsley et al., 2004; Pawson et al., 2008). More-
over, according to their “dual pharmacology,” GnRH analogs
are also characterized by direct anticancer potential via their
interference with growth and survival factors, such as insu-
lin-like growth factor-I, epidermal growth factor, and kera-
tinocyte growth factor (Culig et al., 1994; Montagnani
Marelli et al., 2007). GnRH receptor agonists currently in
clinical use (e.g., leuprolide) are superior to the native hor-
mone (GnRH) in terms of potency because of their high re-
ceptor affinity and improved proteolytic stability (Berger et
al., 1991). However, GnRH analogs are still susceptible to the
action of proteolytic enzymes (Haviv et al., 1992) and have
limited absorption (Zheng et al., 1999) and low bioavailability
(Adjei et al., 1993). As a consequence, these peptides are
administered intramuscularly or subcutaneously and as de-
pot formulations (Sennello et al., 1986; Perez-Marreno et al.,
2002).
During the first days of their administration, GnRH recep-
tor agonists are accompanied by the “flare phenomenon,” in
which the pituitary-gonadal axis is stimulated, thus result-
ing in the extensive release of gonadotrophs (10- and 5-fold
increases in luteinizing hormone and follicle-stimulating hor-
mone concentrations, respectively) and testosterone (Johns
et al., 1990; Labrie et al., 2005). The flare phenomenon is an
undesirable side effect that promotes metastasis. In the
clinic, it can be managed by combined androgen blockade,
which includes the coadministration of an antiandrogen (e.g.,
flutamide) and a GnRH receptor agonist (Wirth et al., 2007).
As an alternative to GnRH receptor agonists, peptide antag-
onists have been synthesized and developed over the years.
The administration of GnRH receptor antagonists does not
cause the flare phenomenon, a considerable advantage in
comparison with GnRH receptor agonists, but these agents
have been associated with other side effects such as acute
inflammation and require higher doses compared with ago-
nists (Labrie et al., 2005; Kirby et al., 2009).
Considering the importance of hormonal therapy for the
treatment of prostate cancer and the current needs for im-
proved therapeutic approaches, we decided to focus on efforts
to discover pharmacokinetically superior and possibly equi-
potent novel GnRH peptide analogs. Although superagonists
have well established clinical benefits, their in vivo stability
remains a limiting factor that most likely prevents them from
exerting any direct effects on tumors (extrapituitary) or caus-
ing rapid desensitization of the GnRH receptor. After the
development and establishment of in vitro and in vivo assays,
coupled with liquid chromatography (LC)-tandem mass spec-
trometry (MS/MS) methodologies (Sofianos et al., 2008), an-
alog 1, a potent stable peptide, was chosen from a screen
among other GnRH receptor peptide agonists/antagonists. In
this article, we report our findings regarding analog 1, [Des-
Gly10,Tyr5(OMe),D-Leu6,Aze-NHEt9]GnRH, a molecule with
the conformational features required for agonistic activity
(Matsoukas et al., 1997; Laimou et al., 2010) and enhanced in
vitro and in vivo stability compared with leuprolide.
Although analog 1 has reduced binding affinity on the
GnRH receptor compared with leuprolide, repeated dosing
studies in mice demonstrated that analog 1 was well toler-
ated and had potency similar to that of leuprolide. Analog 1
was also endowed with significant antiproliferative activity
on prostate cancer cells (LNCaP), similar to that exerted by
leuprolide. On the basis of its pharmacokinetic advantages, it
is likely that the peptide analog in question or analogs based
on this new design will be therapeutically advantageous for
the treatment of endocrine disorders or prostate cancer. Such
pharmacokinetic advantages can be particularly valuable
with respect to local/direct extrapituitary effects that will be
essential for more effective treatment of cancer.
Materials and Methods
Chemicals/Biological Reagents. [Des-Gly10,D-Leu6,Pro-NHEt9]-
GnRH (leuprolide acetate salt), Ac-D-2-Nal-4-chloro-D-Phe--(3-pyri-
dyl)-D-Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2 (cetrorelix acetate
salt), and [Des-Gly10,D-Ala6,Pro-NHEt9]GnRH [internal standard
(IS), acetate salt] were purchased from Bachem AG (Bubendorf,
Switzerland). [Des-Gly10,Tyr5(OMe),D-Leu6,Aze-NHEt9]GnRH (ana-
log 1, acetate salt) was synthesized by the Department of Chemistry,
University of Patras, Patras, Greece (Laimou et al., 2010). All sol-
vents were LC-MS grade. Acetonitrile (Riedel-de Hae¨n, Buchs SG,
Switzerland), water (Sigma-Aldrich GmbH, Munich, Germany), am-
monium acetate (Fluka, Buchs, Switzerland), formic acid (Fluka),
human serum albumin (HSA) (Sigma-Aldrich GmbH), dexametha-
sone (Riedel-de Hae¨n), testosterone (Riedel-de Hae¨n), Trizma base
(Sigma-Aldrich GmbH), sodium chloride (Fluka), sodium phosphate
dibasic (Riedel-de Hae¨n), and -NaDPH were purchased from Sig-
ma-Aldrich GmbH. Dithiothreitol was purchased from AppliChem
GmbH (Darmstadt, Germany). Mouse plasma (CD-1) was purchased
from Charles River Laboratories Italia s.r.l. (Calco, Italy). Tissues
(kidneys and testes) were obtained frommale C57BL/6Nmice. Chinese
hamster ovary-K1 cells were purchased from NEN (Waltham, MA).
125I-(D-Trp6)-GnRH was purchased from PerkinElmer Life and An-
alytical Sciences. The androgen-dependent LNCaP-FGC (lymph node
carcinoma of the prostate-fast growing colony) cell line was obtained
from American Type Culture Collection (Manassas, VA). RPMI 1640
medium was purchased from Seromed, Biochrom KG (Berlin, Ger-
many), and fetal bovine serum was obtained from Invitrogen (Paisley,
Scotland).
Cell Cultures. Cells (passages 35–40) were routinely grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum,
glutamine (1 mM), and antibiotics (100 IU of penicillin G sodium and
100 g/ml streptomycin sulfate) in a humidified atmosphere of 5%
CO2-95% air. In these culture conditions, the duplication period of
LNCaP cells was 48 h.
Animals. All procedures were approved by the bioethics commit-
tee of the institution and the local competent authority on the basis
of the European Directive 86/609 on the protection of animals used
for experimental and other scientific purposes. Male mice of the
C57BL/6N inbred strain (Charles River Laboratories Italia s.r.l.) at
the age of 12 weeks were randomly assigned to groups of five or six
animals. Animal handling occurred before experiments, during
which labeling and weighing took place. Mice were fasted overnight
(12 h) before dosing for pharmacokinetic studies. Dosing solutions of
leuprolide and analogs in saline were administered intraperitone-
ally. Blood sampling was performed by cardiac puncture under iso-
flurane anesthesia. Blood samples (500 l) were collected into low
retention (Axygen, Inc., Union City, CA) microtubes containing 10 l
of heparin (5000 IU/ml) and subsequently centrifuged (10 min at
3000 rpm) for plasma preparation. Plasma was stored in a 80°C
freezer until sample extraction and analysis. Tissues (kidneys and
testes) were removed after the animals were sacrificed using anes-
thesia by isoflurane and cervical dislocation and were washed with
phosphate-buffered saline, weighed, and placed in a 80°C freezer
until analysis.
In Vitro Stability: Mouse Kidney Membranes. Mouse kidney
membrane preparations were obtained on the basis of the procedure
described by Sofianos et al. (2008). Kidneys were washed with PBS,
weighed, and homogenized (0.1 g wet weight/ml) in buffer A (100 mM
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NaCl, 20 mM phosphate, pH 7.4, 0.1 mg HSA/ml, and 1 mM dithio-
threitol) by a Teflon-glass homogenizer. After centrifugation at
1500g for 5 min, the supernatant was centrifuged for 60 min at
100,000g (Sorvall Discovery 100SE ultracentrifuge; Hitachi, Yoko-
hama, Japan). The supernatant was discarded, and the pellet was
washed by addition of buffer B (100 mMNaCl, 20 mM phosphate, pH
7.4, and 0.1 mg HSA/ml) followed by centrifugation at 100,000g for
60 min. After the supernatant was discarded, the pellet was washed
by addition of buffer C (100 mMNaCl and 20 mM phosphate, pH 7.4)
and the protein content was determined by the Bradford assay
(Bradford, 1976). Incubation mixtures consisted of 500 ng/ml peptide
(leuprolide and/ or analog 1) and 4 mg/ml protein in a final volume of
250 l of mouse kidney homogenate. Additional control samples (no
kidney membranes) were prepared for each of the time points tested.
The reaction was stopped by acetonitrile addition, and samples were
stored at 80°C.
Sample extraction (samples left at room temperature to thaw for
20 min) was performed by the addition of 250 l of acetonitrile-water
(50:50) with 0.1% formic acid, followed by brief vortexing and soni-
cation. Proteins were precipitated by stepwise addition of 250 and
500 l of ice-cold acetonitrile followed by brief vortexing. Samples
were subsequently centrifuged (12,000g) for 10 min, and the super-
natant was evaporated in a SpeedVac (SPD1010; Thermo Fisher
Scientific, Waltham, MA) for 90 min at 50°C. An aliquot of 100 l of
mobile phase (see below) was added to each sample, and the sample
was vortexed and transferred to a 96-well plate for analysis. An
1100 series system (Agilent Technologies, Waldbrown, Germany)
equipped with a binary pump, autosampler, vacuum degasser, and
temperature-controlled column compartment was used for analyte
separation by high-performance liquid chromatography. The mobile
phase consisted of solvents A (10% acetonitrile, 90% water, 2 mM
ammonium acetate, and 0.1% formic acid) and B (90% acetonitrile,
10% water, 2 mM ammonium acetate, and 0.1% formic acid). An
Atlantis dC18 m, 2.1  50 mm column (Waters, Milford MA) was
used at a flow rate of 0.3 ml/min. A linear gradient (run time of 15
min) from 95% A-5% B to 50% A-50% B over 5 min and 50% A-50%
B up to 9 min was used for the chromatographic separation of
peptides of interest. Mass spectrometry was performed on an API
4000 Q-TRAP LC-MS/MS system fitted with a TurboIonSpray source
and a hybrid triple quadrupole hybrid linear ion trap mass spectrom-
eter (Applied Biosystems, Concord, ON, Canada). The instrument
was operated in positive ion mode under the following conditions:
IonSpray voltage, 5500 V; source temperature, 550°C; curtain gas
(nitrogen) at 20; collision gas (nitrogen) at 5; ion source gas 1 (air) at
40; and ion source gas 2 (air) at 45 (all arbitrary units). Analog 1
(mol. wt. 1209.4 g/mol) was monitored by using the multiple-reaction
monitoring (MRM) transitions of m/z 605.7 3 249.2 and 605.7 3
285.4. The MRM transitions ofm/z 605.53 249.1 and 605.73 221.1
were used for the detection of leuprolide (mol. wt. 1209.4 g/mol).
In vitro peptide stability was determined as a function of time;
using the corresponding MRM transitions for each analyte, the peak
areas for analog 1 and/or leuprolide (peptide concentration of 500
ng/ml) at t  0 were set as 100%. Those peak areas were compared
with the peak areas derived from samples at t  0.5, 1, and 2 h. The
mean intra-assay coefficient of variation based on control samples
(500 ng/ml peptide) was less than 10%. The interassay coefficients of
variation for the determination of leuprolide and analog 1 were 6.6
and 6.9%, respectively. Peptide monitoring by LC-MS/MS ensured
specificity because both peptides had characteristic retention times
(6.79 0.01 min for leuprolide and 7.19 0.01 min for analog 1) and
corresponding MRM transitions. In addition, analyses of blank sam-
ples confirmed the absence of interference and established the selec-
tivity of the assay.
Metabolism Studies: Mouse Kidney Membranes. After incu-
bation of analog 1 with mouse kidney membrane preparations, me-
tabolites were identified by a modification of the LC-MS/MS-based
approach described above using the instrument’s information-depen-
dent acquisition feature and combining Q3 scanning followed by
enhanced product ion (EPI). Information-dependent acquisition cri-
teria were set so that a number of the most intense peaks (up to 8)
would be selected for EPI analysis with a collision energy of 45  5
V (leuprolide) and/or 45  10 V (analog 1). The semiquantitative
analysis for the major metabolites identified herein was achieved by
using the MRM-positive mode, as described above. Two major met-
abolic products were identified: a tripeptide (M-III) and a pentapep-
tide (M-V). M-III (mol. wt. 452.4 g/mol) was monitored based on the
MRM transitions ofm/z 453.43 176.1 and 453.43 110.2. The MRM
transitions ofm/z 688.83 150.2 and 688.83 263.2 were used for the
detection of M-V (mol. wt. 687.8 g/mol).
In Vivo Stability and Pharmacokinetic Studies. Analog 1
was administered to male C57BL/6N mice at 1 mg/kg i.p., and blood
samples were obtained at t  1, 2, 4, and 6 h postdose (n  5). In a
parallel test group (n  5), leuprolide was administered at 1 mg/kg.
For the quantification of peptides in plasma, stock solutions of leu-
prolide or analog 1 were prepared in acetonitrile-water (50:50) with
0.1% formic acid in the range of 0.5 to 5000 ng/ml. A linear peptide
analog of both peptides was used as the IS at the concentration of 600
ng/ml. A set of solutions at two different concentrations (50 and 500
ng/ml) was prepared, serving as the quality control (QC) samples.
Calibration curves (0.5–500 ng/ml for leuprolide and 5–2500 ng/ml
for analog 1) and QC samples (50 and 500 ng/ml) were prepared in
plasma by addition of 20 l of leuprolide or analog 1 solutions and 25
l of the IS solution to 50 l of mouse plasma. Samples were pre-
pared for LC-MS/MS analysis by protein precipitation as described
above. Peptide quantification was performed in the MRM-positive
mode. For leuprolide and IS detection, mass spectrometry-based
quantification methods were developed and validated previously (So-
fianos et al., 2008). Analog 1 was monitored in mouse plasma using
the MRM transitions of m/z 605.7 3 249.2 and 605.7 3 221.4. A
nine-point calibration curve was constructed using a 1/x weighted
linear regression model (r 0.999). On the basis of concentrations at
50 and 500 ng/ml, the intra-assay coefficient of variation for the
assay was less than 6% for leuprolide detection and less than 5% for
the analysis of analog 1. The interassay coefficients of variation for
analog 1 and leuprolide were 6 and 7%, respectively.
Assay specificity and selectivity was ensured by using an LC-
MS/MS methodology (retention time and MRM transitions charac-
teristic of the analyte) and analyzing blank samples to test for
interferences. Based on QC samples at 50 and 500 ng/ml, the accu-
racy of the assays for the determination of analog 1 and leuprolide in
mouse plasma was 100 and 97%, respectively. The lower limit of
quantification for both peptides in mouse plasma was 0.5 ng/ml,
defined as the concentration that yielded a peak with a signal/noise
ratio of 10 and at least 3 times the response compared with signal
from blank extracts (samples not spiked with peptide). The accuracy
and precision of the measurement at the concentration of 0.5 ng/ml
were within 20%.
Binding to the Human GnRH Receptor. A screening protocol
was followed for the ranking of GnRH analogs (including analog 1) in
terms of their binding affinities to the human GnRH receptor. In
brief, competition binding studies were performed according to the
method of PerkinElmer Life and Analytical Sciences. Frozen mem-
brane homogenates from Chinese hamster ovary-K1 cells stably
expressing the human GnRH receptor, purchased from PerkinElmer
Life and Analytical Sciences, were thawed and diluted in assay
buffer (25 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM CaCl2, and 0.5%
bovine serum albumin) at a protein concentration of 0.07 mg/ml.
Aliquots of diluted membrane suspension (150 l) were incubated
with increasing concentrations of GnRH analogs in the presence of
0.2 nM 125I-(D-Trp6)-GnRH (PerkinElmer Life and Analytical Sci-
ences) in a final volume of 0.2 ml. The mixtures were incubated at
27°C for 1 h and then filtered using a Brandel cell harvester through
Whatman GF/C glass fiber filters, presoaked for 1 h in 0.5% poly-
ethylenimine at 4°C. The filters were washed nine times with 0.5 ml
of ice-cold 50 mM Tris-HCl, pH 7.4, and the filters were assessed for
radioactivity in a gamma counter (LKB Wallac 1275 minigamma,
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80% efficiency). Specific 125I-(D-Trp6)-GnRH binding was defined as
total binding less nonspecific binding in the presence of 1000 nM
(D-Trp6)-GnRH. Data for competition binding were analyzed by non-
linear regression analysis, using GraphPad Prism 4.0 (GraphPad
Software, Inc., San Diego, CA), and log IC50 values were obtained by
fitting the data from competition studies to a one-site competition
model. The Ki values were determined from competition data and the
equation, Ki  IC50/(1  L/KD) (Cheng and Prusoff, 1973), where L is
the concentration of radioligand and KD is the affinity of radioligand
binding, determined from saturation studies performed by Perkin-
Elmer Life and Analytical Sciences and under the same experimental
conditions used in the present study.
To further confirm the binding to the GnRH receptor, analog 1 was
evaluated in a radioligand binding assay by Ricerca Biosciences,
LLC (Concord, OH) as described in the literature (Halmos et al.,
1996), using human recombinant Chem-1 cells, 0.05 nM 125I-(D-
Trp6)-GnRH (ligand), and 1 M (D-Trp6)-GnRH (nonspecific ligand).
Reference standards were run as an integral part of each assay to
ensure the validity of the results obtained. IC50 values were deter-
mined by a nonlinear, least-squares regression analysis using Ma-
thIQ (ID Business Solutions Ltd., Guildford, Surrey, UK). The Ki
values were calculated (Cheng and Prusoff, 1973) using the observed
IC50 of the tested compound, the concentration of radioligand used in
the assay, and the historical values for the KD of the ligand (obtained
experimentally at Ricerca Biosciences, LLC).
Efficacy Studies (Testosterone Quantification in Mouse
Plasma). The ability of analog 1 to elicit testosterone release (GnRH
receptor agonism) in mice was investigated and compared with that
of leuprolide. Analog 1 was administered to male C57BL/6N mice at
1 mg/kg, and blood sampling was conducted by cardiac puncture
under isoflurane anesthesia at t  1, 2, 4, and 6 h postdose (n  5).
The same approach was followed in the case of vehicle (saline)- and
leuprolide (1 mg/kg)-treated animals (n  5). Peptides and testoster-
one were measured in mouse plasma by an LC-MS/MS-based assay.
Stock solutions of testosterone (0.125–250 ng/ml) and dexametha-
sone (served as the IS for testosterone quantification) were prepared
in acetonitrile-water (50:50) with 0.1% formic acid. Calibration
curves (0.2–100 ng/ml) and QC samples (1, 5, 10, and 40 ng/ml) were
prepared by adding 20 l of testosterone solutions and 25 l of
dexamethasone solution (200 ng/ml) to 50 l of female CD-1 mouse
plasma. Female CD-1 plasma was devoid of testosterone and, hence,
was used for the construction of the standard curves and QC sam-
ples. A similar extraction protocol (protein precipitation) and chro-
matographic conditions as described above were used to achieve the
separation of testosterone, dexamethasone, and peptides. Quantifi-
cation was performed in the MRM-positive mode. For the detection of
testosterone (mol. wt. 288.4 g/mol), the MRM transitions ofm/z 289.4
3 109.1 and 289.43 97.2 were optimized, and dexamethasone (mol.
wt. 392.5 g/mol) was monitored using the MRM transition of m/z
393.53 237.2. A nine-point calibration curve was constructed using
a 1/x weighted linear regression model (r  0.993).
On the basis of QC samples at 1 and 10 ng/ml, the intra- and
interassay coefficients of variation were less than 10 and equal to
7%, respectively. The accuracy of the testosterone assay was 98%.
The retention times (expressed in minutes) obtained were character-
istic of the analytes: 8.92  0.02 (testosterone), 7.92  0.01 (dexa-
methasone), 6.69  0.01 (analog 1), 6.22  0.02 (leuprolide), and
6.67  0.01 (IS). The absence of interference was further confirmed
by analyzing blank samples (female CD-1 mouse plasma). The lower
limit of quantification for testosterone in mouse plasma was 0.05
ng/ml, defined as the concentration that yielded a peak with a signal/
noise ratio of 10 and at least 3 times the response compared with
signal from blank extracts (samples not spiked with testosterone).
The accuracy and precision of the measurement at the concentration
of 0.05 ng/ml were within 20%. The LC-MS/MS method that was
developed and applied to our study ensured the simultaneous quan-
tification of testosterone and peptide agonists in both plasma and
testis from the same limited sample.
Dose-Response Study. To investigate and establish a dose-re-
sponse relationship on the administration of analog 1 in mice, analog
1 was dosed intraperitoneally to male C57BL/6N mice. A dose-re-
sponse relationship was also investigated and determined for leu-
prolide. The peptides were dosed at 0.1, 1, 10, and 1000 g/kg, and
blood samples were obtained by cardiac puncture under isoflurane
anesthesia at t  1 h postdose (n  5). The same approach was
followed in the case of vehicle (saline)-treated animals (n  5).
Peptides and testosterone were quantified in mouse plasma as de-
scribed above.
GnRH Receptor Agonism. To further confirm that testosterone
release results from the binding of analog 1 to the GnRH receptor
(agonism), analog 1 was dosed intraperitoneally to male C57BL/6N
mice in the presence and absence of a known GnRH receptor antag-
onist, cetrorelix. Cetrorelix was dosed (intraperitoneally) at 1 mg/kg
and after 15 min, analog 1 was dosed either at 1 or 10 g/kg. In a
different group, animals were treated with vehicle (saline) and after
15 min, analog 1 was administered either at 1 or 10 g/kg. Likewise,
GnRH agonism was investigated upon leuprolide dosing (at 1 g/kg).
Blood sampling was conducted by cardiac puncture under isoflurane
anesthesia at t 1 h postdose (n 5). Quantification for peptide and
testosterone was performed as described above. Cetrorelix (mol. wt.
1431.1 g/mol) was monitored by LC-MS/MS using the MRM transi-
tions of m/z 716.2 3 154.3 and 716.2 3 569.4.
Cell Proliferation Assays. LNCaP cells were plated (100,000
cells/dish) in 10-cm dishes in standard culture medium. Cells were
allowed to attach and start growing for 3 days; the seeding media
were then changed to experimental media. Cells were treated, daily,
for 7 days, with either leuprolide or with analog 1 (106, 108, and
1010 M); the medium was changed every 2 days. At the end of the
treatment, cells were harvested and counted by hemocytometer. The
doses of the GnRH analogs have been chosen on the basis of previous
articles from Dr. Limonta’s laboratory (Limonta et al., 1992, 1999).
Efficacy Based on GnRH Desensitization and Testosterone
Depletion. To investigate and determine the ability of analog 1 to
cause testosterone ablation upon repeated administration, a long-
term repeated dosing study was conducted. Analog 1 was dosed once
a day intraperitoneally to male C57BL/6N mice at 500 g/kg for 20
days (n  6). Vehicle (saline)-treated animals served as a control
group (n  6). The pharmacological effect of analog 1 was compared
with that of leuprolide (n  6). Blood samples were obtained by
cardiac puncture under isoflurane anesthesia 1) at day 0, t  2 h
postdose, 2) at day 9, t  2 h postdose, and 3) at day 20. To further
confirm testosterone depletion, blood samples were obtained at day
20, t  2 h postdose. Testes were removed at days 0, 9, and 20 and
weighed and subsequently histopathologically examined; testes were
fixed in 10% formalin overnight at 4°C, followed by embedding,
sectioning, and staining with hematoxylin and eosin and finally were
examined under a light microscope. Analog 1, leuprolide, and testos-
terone concentrations were determined in both mouse plasma and
testis by LC-MS/MS with minor modifications; the standard curve
for the analysis of testosterone in testis was constructed using male
mouse testis homogenate that was treated with activated charcoal
for steroid depletion as described by Green and Leak (1987).
Statistical Analysis. The results presented herein are expressed
as means  S.D. Statistical analyses were performed by the Stat-
Graphics Centurion 15.206S program. Statistical significance was
determined by using Student’s t test. Data from proliferation assays
were analyzed by a Bonferroni test after one-way analysis of
variance.
Results
Binding Data. The IC50 and Ki for analog 1 were 16 and
14 nM, respectively. (D-Trp6)-GnRH was used as a control for
the study, giving IC50 and Ki values of approximately 0.2 nM
(the IC50 for leuprolide is approximately 0.3 nM on the basis
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of historic data provided by Ricerca Biosciences, LLC). The
results suggest that the biological activity of analog 1 is
mediated through potent binding on the GnRH receptor.
In Vitro Stability and Metabolism Studies. The incu-
bation of analog 1 with mouse kidney membrane prepara-
tions resulted in two major metabolic products: a tripeptide
(M-III: pGlu1-His2-Trp3-OH) and a pentapeptide [M-V: Tyr-
(OMe)5-D-Leu6-Leu7-Arg8-Aze9-NHEt]. The proposed struc-
tures of metabolites of analog 1 are shown in Fig. 1A. Our
data support the susceptibility of the Trp3-Ser4 and Ser4-
Tyr5 peptide bonds, a consistent finding based on studies
that focus on GnRH and other analogs (Berger et al., 1991;
Brudel et al., 1994). The approach described allowed the
semiquantification of analog 1 (degradation of peptide) and
M-III and M-V (formation of metabolites) as a function of
time, depicted in Fig. 1B. Metabolite assignments were based
on the MS andMS/MS spectra of analog 1 and its correspond-
ing metabolites. The MS and MS/MS spectra for metabolite
M-V (m/z at 688.8) are represented in Fig. 1, C and D. The
major product ions at m/z 150.2 and 263.2, shown in Fig. 1D,
correspond to the immonium ion of the methylated Tyr5 and
the a2 fragment ion of M-V. Likewise, the major product ions
for M-III atm/z 110.2 and 221.1 correspond to the immonium
ion of His2 and the a2 fragment ion of M-III (data not shown).
A leuprolide metabolism/in vitro stability study was also
performed, in which two major metabolites were also de-
tected: the tripeptide described above (M-III) and a penta-
peptide (M-I: Tyr5-D-Leu6-Leu7-Arg8-Pro9-NHEt), being con-
sistent with those metabolites reported in the literature
(Ueno and Matsuo, 1991). Analog 1 and leuprolide share a
rather common peptide sequence, with differences at position
5 (analog 1 is methylated at tyrosine) and position 9 (analog
1 has an azetidine instead of proline). On the basis of the
structural similarities of analog 1 and leuprolide, as was
expected, M-III was a common metabolic product for the two
peptides.
To determine the in vitro stability of analog 1 (and leupro-
lide) as a function of time, the compounds were incubated
with mouse kidney membrane preparations as described.
After extraction of the analytes and detection by the LC-
MS/MS methodology, the peak areas for both peptides were
set as 100% at t  0. Those peak areas were subsequently
compared with the peak areas derived from samples at t 
0.5 h, t  1 h, and t  2 h. Analog 1 was found to be
significantly more stable in comparison with leuprolide; at
t  2 h, leuprolide was extensively metabolized by mouse
kidney membrane preparations, whereas 11% of analog 1
remained intact (Fig. 2A). This in vitro system also allowed
compound ranking of selected GnRH analogs. The absence of
metabolism of the described peptides (leuprolide, analog 1) in
mouse liver microsomes (data not shown) further supports
the fact that the kidney is the major site for the metabolism
of leuprolide and the analog described (Carone and Peterson,
1980).
Fig. 1. A, the proposed metabolic products after the incubation of analog
1 with mouse kidney membranes. B, peptide degradation and metabolite
(M-III and M-V) formation were monitored as a function of time. C, MS
spectrum characteristic of metabolite M-V. D, EPI spectrum of M-V of ion
m/z 689. The major ions shown (m/z 150.2 and 263.2) correspond to the
immonium ion of methylated Tyr5 and the a2 fragment of M-V. amu,
atomic mass units.
Pharmacology of a Stable GnRH Analog 617
In Vivo Stability and Pharmacokinetic Studies. A
pharmacokinetic study was conducted in mice for the evalu-
ation of the in vivo stability of analog 1. In parallel, the
pharmacokinetic profile of leuprolide was also evaluated. A
graphical representation of peptide concentrations for both
analog 1 and leuprolide in mouse plasma at t  1 h, t  2 h,
t  4 h, and t  6 h postdose is depicted in Fig. 2B. Analog 1
exhibited a profound pharmacokinetic advantage compared
with leuprolide on the basis of absolute plasma concentra-
tions and areas under the curve (AUCs). Analog 1 dosing
resulted in an AUC1–6 h  479.5 ng  h/ml, whereas the AUC
value for leuprolide dosing was AUC1–6 h  136.8 ng  h/ml.
Plasma peptide concentrations determined at all time points
for both peptides tested showed relatively low intersubject
variation. In this setting, the described in vivo pharmacoki-
netic protocol was also used as a comparative platform be-
tween leuprolide and other peptide analogs.
Functional Agonism of the GnRH Receptor-Testos-
terone Quantification inMouse Plasma after Dosing in
Mice. An efficacy study was conducted in which testosterone
release was monitored upon the administration of analog 1 in
mice (agonism of the GnRH receptor). Likewise, testosterone
concentrations were determined in the plasma of leuprolide-
treated mice. Testosterone plasma concentrations as a func-
tion of time (t  1–6 h postdose) are shown in Fig. 3A.
Testosterone measurements in vehicle-treated mice were low
as expected and in agreement with our previous studies
(Sofianos et al., 2008). In comparison, testosterone concen-
trations in leuprolide-treated mice were significantly higher
at t  1 to 6 h postdose (, p  0.001 versus vehicle-treated
mice). Testosterone release due to analog 1 dosing was sug-
gestive of agonism (, p  0.001 at t  1 h, t  2 h, and t 
4 h versus vehicle-treated mice), showing a pattern similar to
that with leuprolide treatment. In addition, Testosterone
AUC1–6 h values were equal to 244.1 and 154.9 ng  h/ml for
leuprolide and analog 1 dosing, respectively.
To explore potential dosing regimens for efficacy studies, a
dose-response relationship was established for both analog 1
and leuprolide treatment by dosing experiments in mice at
0.1, 1, 10, and 1000 g/kg. Peptide plasma concentrations (1
h postdose) as a function of dose are depicted in Fig. 3B.
Testosterone concentrations seemed to reach a plateau at
doses higher than 10 g/kg (data not shown). To demonstrate
the specificity of the effects of testosterone release (i.e., bind-
Fig. 2. A, the in vitro stability of analog 1 and leuprolide
after peptide incubation with mouse kidney membrane
preparations. B, the pharmacokinetic profiles (in vivo sta-
bility) of analog 1 and leuprolide after peptide administra-
tion in mice (n  5) at 1 mg/kg i.p.
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ing to the GnRH receptor and agonism by analog 1), the
dosing of analog 1 was evaluated in the presence and absence
of cetrorelix (GnRH receptor antagonist). The administration
of analog 1 in the absence of cetrorelix resulted in a robust
plasma testosterone release. In contrast, no testosterone was
released when analog 1 was administered after cetrorelix
administration. A similar result was obtained upon leupro-
lide dosing in the presence and absence of cetrorelix (Fig. 3C).
Fig. 3. A, testosterone release (functional ago-
nism) upon analog 1 and leuprolide intraperito-
neal dosing in mice (n  5). The plasma testos-
terone concentration in vehicle-treated mice was
low as expected and in agreement with previous
studies. The testosterone concentration in leu-
prolide-treated mice was significantly higher at
each time point tested (, p  0.001 versus
vehicle-treated mice). Testosterone release due
to analog 1 dosing was suggestive of agonism
(, p 0.001 versus vehicle-treated mice at t
1 h, t  2 h, and t  4 h), showing a pattern
similar to that with leuprolide treatment. B,
peptide plasma concentrations (1 h postdose) as
a function of dose. In searching for appropriate
doses for efficacy studies, a dose-response rela-
tionship was established for both analog 1 and
leuprolide by dosing intraperitoneal experi-
ments in mice at 0.1, 1, 10, and 1000 g/kg (n 
5). Testosterone concentrations seemed to reach
a plateau at doses higher than 10 g/kg (data not
shown). C, plasma testosterone concentration
upon analog 1 and leuprolide dosing in mice (n
5) in the presence and absence of cetrorelix to
demonstrate the specificity of the effects of tes-
tosterone release. No response (no testosterone
release) was observed in the presence of cetrore-
lix. Testosterone release is observed by the ad-
ministration of peptides (either leuprolide or an-
alog 1) in the absence of cetrorelix. Values are
presented as the mean  S.D.
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Antiproliferative Effect of Analog 1 on LNCaP Cells.
The effect of analog 1 (1010–106 M) on the proliferation of the
androgen-dependent LNCaP cells was investigated. Cells
treated with the GnRH receptor agonist leuprolide served
as the positive control. Analog 1 significantly inhibited the
proliferation of LNCaP cells at 1 M (, p  0.05 versus con-
trols), showing a pharmacological activity similar to that of
leuprolide (Fig. 4).
Efficacy Based on GnRHDesensitization and Testos-
terone Depletion. The effect of repeated dosing of analog 1
(500 g/kg per day) was investigated in mice for 20 days and
compared with effects caused by leuprolide. Testosterone
concentrations in mouse plasma are summarized in Table 1.
At day 0, peptide dosing resulted in significant testosterone
release in mouse plasma compared with that in vehicle-
treated mice (, p 0.001 for both analog 1- and leuprolide-
treated mice). At day 9, plasma testosterone concentrations
of peptide-treated mice were decreased compared with those
of their counterparts at day 0 but were higher than those of
vehicle-treated mice, suggesting that receptor desensitiza-
tion had not been accomplished. At day 20, peptide dosing
resulted in a decrease by almost 50% in plasma testosterone
concentration (not statistically significant), compared with
that in vehicle-treated mice. With respect to testis testoster-
one measurements, at day 0, peptide dosing resulted in sig-
nificant testosterone release and high testis testosterone con-
centrations compared with those of vehicle-treated mice
(, p  0.001 for both analog 1- and leuprolide-treated
mice). After a 20-day repeated dosing regimen for both ana-
log 1 and leuprolide, testis testosterone was significantly
decreased (, p  0.05) in comparison with that in vehicle-
treated mice (Fig. 5A). The testis weight of mice treated with
500 g/kg analog 1 was decreased by 51% (, p  0.001
versus vehicle-treated mice), whereas no body weight losses
were observed. Testis atrophy was also present in leuprolide-
treated mice (Fig. 5B). Histopathological examination fur-
ther confirmed that analog 1 and leuprolide treatment re-
sulted in remarkable atrophy of testis in mice. As shown in
Fig. 6, the seminiferous epithelium became thinner and the
number of the spermatogenic cells was decreased compared
with that of the vehicle-treated mice.
Discussion
Based on the highly influential findings of Huggins (1963)
and Schally et al. (1984), hormonal or chemical castration via
the GnRH receptor became a well established strategy for the
treatment of hormone-dependent cancers. Hormone-depen-
dent cancers are not limited to the prostate and include those
in other reproductive tissues such as the breast, ovaries, and
endometrium. Numerous GnRH analogs have been synthe-
sized in the context of the hormonal therapy for prostate
cancer with the aim of achieving medical castration. Overall,
systematic work has resulted in the synthesis of GnRH re-
ceptor agonists and antagonists, either peptides, linear or
cyclic (Keramida et al., 2006), or small organic molecules
(	nderes et al., 2003). More recently, degarelix, a novel
GnRH receptor antagonist, was discovered. Degarelix, shown
to be as effective as leuprolide in reducing testosterone in
clinical trials without any evidence of systemic allergic reac-
tions (Persson et al., 2009), was approved by the U.S. Food
and Drug Administration and the European Medicines
Agency for the treatment of advanced hormone-dependent
prostate cancer (2009 and 2010, respectively). In addition, in
the past few years diverse cytotoxic analogs targeting the
GnRH receptor (cytotoxic radicals coupled to GnRH analogs
that function as carriers) have been synthesized and evalu-
ated with the intention of targeted chemotherapy (Mezo and
Manea, 2010).
Although extensive research has been performed in the
field of hormonal therapy, poor pharmacokinetic properties
still characterize GnRH peptide analogs. Poor stability of
GnRH analogs necessitates their subcutaneous administra-
tion (depot formulations) and leads to several side effects
such as leukocytoblastic vasculitis (Turk et al., 2007) and
injection site granulomas (Shiota et al., 2007). Most likely,
GnRH analogs in clinical use achieve the desired pharmaco-
logical effects by action primarily on the pituitary and to a
much lesser extent by direct antiproliferative effects on tu-
mor cells. We hypothesize that stable analogs of such super-
agonists would be advantageous, either by allowing a reduc-
tion in dosing frequency or by allowing the use of analogs
Fig. 4. Antiproliferative effect of analog 1 on LNCaP cells
(hormone-dependent prostate cancer cell line). LNCaP cells
were treated daily for 7 days with either leuprolide (posi-
tive control) or with analog 1 (1010–106 M). C, untreated
controls. Results are expressed as the number of cells per
dish and represent the results from three separate exper-
iments. Values are presented as the mean  S.D. , p 
0.05 versus C.
TABLE 1
Testosterone concentrations in plasma after a 20-day repeated dosing
of analog 1 or leuprolide
Data shown represent mean values  S.D.
Days
Plasma Testosterone
Vehicle-
Treated Mice Leuprolide-Treated Mice
Analog 1-
Treated Mice
ng/ml
0 0.16  0.03 25.3  4 20.9  7
20 0.46  0.37 0.20  0.08 0.20  0.17
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that act directly on the tumor, with possible additive effects
and subsequent enhancements in efficacy.
Because prostate cancer is our research area of interest, a
novel GnRH receptor peptide agonist, analog 1 was synthe-
sized with the aim of enhancing in vivo stability based on the
design of leuprolide, a potent drug for the treatment of pros-
tate cancer and other endocrine disorders (e.g., precocious
puberty). In this article, we have described experimental
findings regarding evaluation of analog 1, using leuprolide as
a positive control. The novel peptide analog exhibited signif-
icant in vitro and in vivo metabolic stability, a critical result
suggesting that modifications at positions 5 (tyrosine meth-
ylation) and 9 (azetidine instead of proline) improve meta-
bolic stability. In comparison with analog 1, leuprolide was
metabolized at a faster rate by our in vitro system and after
dosing in mice it was cleared rapidly from the plasma.
It should be noted that the enhanced metabolic stability
observed with analog 1 compared with that with leuprolide is
primarily due to methylation on the tyrosine residue, pre-
sumably due to steric hindrance at the site of cleavage (5–6
position) by endopeptidases. However, data from studies in
our laboratory (not shown) suggest that the replacement of
proline with azetidine at position 9 has an additive effect
when it comes to the metabolic stability of analog 1. Regard-
ing the reduced binding affinity of analog 1 compared with
that with leuprolide, we believe that it is consistent with
analysis of ligand interactions with the GnRH receptor (Seal-
fon et al., 1997) according to which methylation of tyrosine on
GnRH eliminates one of the two postulated hydrogen bonds
with Arg8, thus leading to reduced binding affinity (Laimou
et al., 2010). Although no single residue is crucial for GnRH
activity, the change of proline to azetidine in position 9 is not
expected to significantly affect binding affinity. We estab-
lished early on in our screening efforts an excellent correla-
tion between in vitro data (incubation of peptide with mouse
kidney membranes) and in vivo stability (administration of
peptide in mice and plasma monitoring as a function of time).
Because it has been shown that tissue-specific metabolic
degradation of the native hormone (GnRH) by the met-
alloendopeptidase EP24.15 generates biologically active
peptides (Cleverly and Wu, 2010), we consider understand-
ing of the metabolism of new analogs an essential aspect of
future compound optimization. It should be noted that
although we have a good understanding of the metabolism
of analog 1, the pharmacological significance of the metab-
olites presented in this article (M-III and M-V) has not
been evaluated. However, based on the literature (M-III is
also a metabolite of leuprolide), we hypothesize that those
metabolites are not active.
A facile preclinical mouse model was developed in the context
of our objectives. Intraperitoneal administration was selected,
because oral administration was not practical due to the low
Fig. 5. A, testis testosterone concentrations after analog 1
or leuprolide (500 g/kg) dosing in mice for 20 days (n  6).
At day 0, high testis testosterone concentrations are ob-
tained compared with those in vehicle-treated mice (, p 
0.001 for both analog 1- and leuprolide-treated mice). After
a 20-day repeated dosing regimen for both analog 1 and
leuprolide, testis testosterone was significantly decreased
below the basal testosterone concentrations (, p  0.05) as
defined by testosterone measurements in vehicle-treated
mice. B, testis atrophy as a result of peptide repeated
dosing. The testis weight of mice treated with 500 g/kg
analog 1 was decreased by 51% (, p  0.001 versus
vehicle-treated mice), whereas no body weight losses were
observed. Testis atrophy was also present in leuprolide-
treated mice. Values are presented as the mean  S.D.
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bioavailability of the peptides that were tested. The LC-MS/MS-
based quantification of the selected bioactive peptides and their
correspondingmetabolites as well as the selective monitoring of
biomarkers (e.g., testosterone) in response to drug dose, in
plasma and testes, combined with the appropriate preclinical
mouse model, represents a distinctive approach. The mouse
model described in this article is particularly valuable, because
1) the human GnRH receptor is homologous to the mouse re-
ceptor (Millar et al., 2004), 2) information on in vitro and in vivo
stability can be obtained with a relatively small amount of
peptide (1–2mg), 3) information on the GnRH receptor agonism
(receptor specific in vivo modulation) can be obtained by using
testosterone as a marker, 4) it allows the determination of the
dosing regimen required for efficacy based on action on the
pituitary, and 5) it can become the basis of follow-up experi-
ments on genetically modified mouse animal models or other
tumor xenografted mouse models (Sharpless and Depinho,
2006; Morgan et al., 2008).
The robust sensitive methodology that we developed for
the quantification of testosterone in mouse plasma (0.05–100
ng/ml) or determination of testosterone in testis (2–2000
ng/g) gives us an excellent understanding of compound effi-
cacy assessment. Because endogenous testosterone plasma
concentrations of control animals are low (
0.2 ng/ml), by
using our methodology it is difficult to establish “castration”
plasma values for treated animals, an anticipated effect after
dosing. However, the high concentrations of testosterone in
testis (average control values of 305 ng/g) allowed us to easily
distinguish between control and treated values. After the
20-day treatment, average testis concentrations in leupro-
lide- or analog 1-treated animals were 58 and 118 ng/g,
respectively. Moreover, the testis weights of the treated an-
imals were significantly lower in comparison with those of
the control group (atrophy induced by dosing), thus making
the differences in testosterone testis concentration between
control and peptide-treated animals even more pronounced.
Although the binding affinity of analog 1 on the GnRH re-
ceptor was not as high as the binding affinity of leuprolide
(
15 versus 1 nM), the in vivo efficacy between the two
analogs was similar (at the tested dose), suggesting that the
enhanced stability or bioavailability of analog 1 compensates
for binding affinity differences. Proliferation studies based on
a hormone-dependent prostate cancer cell line (LNCaP cells)
indicated that analog 1 was as potent as the superagonist
leuprolide in terms of inhibiting cell proliferation. It is pos-
sible that analog 1 can play a significant role for the treat-
ment of hormone-dependent cancers, by acting not only at
the pituitary level (thus suppressing the pituitary-testicular
axis) but also by exerting antitumor activity directly on can-
cer cells, as has been previously shown for other GnRH
agonists (Maudsley et al., 2004; Montagnani Marelli et al.,
2006). On the basis of the binding affinities of both analogs
(leuprolide or analog 1), perhaps antiproliferative effects
should have been expected at nanomolar concentrations.
However, our studies with the LNCaP cell line showed that
significant effects were only observed at the 106 M concen-
tration. Although recent studies that used the superagonist
D-Trp6-GnRH-I as a positive control show that with certain
cell lines (e.g., transfected HEK293 cells), growth inhibition
can be achieved at 5 nM agonist concentrations (Morgan et
al., 2008); the same studies demonstrate elegantly that cell
receptor levels and cell context are critical for cell responses.
Thus, the potential of analog 1 for the treatment of prostate
cancer will have to be further investigated by taking into
consideration GnRH receptor levels and cell context and test-
ing in animal models that address antiproliferative effects.
In conclusion, our belief is that the discovery of GnRH
Fig. 6. A, testis from vehicle-treated mice demonstrating normal semi-
niferous epithelium (hematoxylin and eosin; original magnification,
400). B, testis from mice treated with 500 g/kg leuprolide. C, testis
from mice treated with 500 g/kg analog 1, demonstrating a significant
decrease in spermatogenic cells (hematoxylin and eosin; original magni-
fication, 400).
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analogs, such as analog 1 or analogs based on this new design
with features that lead to enhanced in vivo stability and in
vivo potency similar to that of leuprolide could result in
valuable alternatives for the treatment of prostate cancer.
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